From the U.S. Food and Drug Administration (FDA), released July 6, 2022:The Emergency Use Authorization (EUA) for Paxlovid was revised by FDA on July 6, 2022, authorizing state-licensed pharmacists to prescribe Paxlovid to eligible patients with certain limitations.
“The FDA recognizes the important role pharmacists have played and continue to play in combating this pandemic; authorizing state-licensed pharmacists to prescribe Paxlovid could expand access to timely treatment for some patients who are eligible to receive this drug for the treatment of COVID-19,” said Patrizia Cavazzoni, MD, director for the FDA’s Center for Drug Evaluation and Research.
Print Page
Email to a Friend